Surrey Heartlands

Joint Formulary & PAD

Nortriptyline - Pain (Neuropathic)

You are here : Home > Formulary Search > Nortriptyline - Pain (Neuropathic)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

Guidelines (Local)
Neuropathic Pain Guidelines for Primary Care - Oct 20
Guidelines (National)
NICE Clinical guideline [CG173] : Neuropathic pain in adults: pharmacological management in non-specialist settings

PAD Profile

ChemicalSubstance :
Nortriptyline
Indication :
Pain (Neuropathic)
Group Name :
Keywords :
neuropathic pain, Tricyclic antidepressants, TCAs, tricyclics, PHN, post herpetic neuralgia, postherpetic neuralgia, diabetic neuropathy
Brand Names Include :
Allegron
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Nortriptyline is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Pain (Neuropathic).

Committee Recommendations (2)

07 Oct 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee recommends that nortriptyline for use in neuropathic pain should remain as unsuitable for prescribing and agreed to assign it a NON-FORMULARY status for this indication

There appears to be no evidence available to recommend this off label treatment. It is not recommended in NICE guidance (CG173) "Neuropathic pain in adults: pharmacological management in non-specialist settings ".
Amitriptyline is the only tricyclic recommended by NICE. It recommends a switch to another class of drug if amitriptyline is not tolerated or contra-indicated

See guidelines below

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.